Singapore markets open in 1 hour 42 minutes

Novo Nordisk A/S (0TDD.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
122.95-1.87 (-1.50%)
At close: 07:13PM GMT
Full screen
Previous close124.82
Open124.90
Bid0.00 x 0
Ask0.00 x 0
Day's range122.95 - 124.90
52-week range68.37 - 125.00
Volume14,845
Avg. volume21,033
Market cap2.796B
Beta (5Y monthly)0.18
PE ratio (TTM)0.41
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Why This 1 Medical Stock Could Be a Great Addition to Your Portfolio

    The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

  • Reuters

    GRAPHIC-Drugs, fashion and chips - the STOXX 600's 'Magnificent 4'

    European shares have been caught up in the AI-fuelled euphoria sweeping equity markets everywhere to record highs, with the STOXX 600 being the latest index to hit that milestone. With a market value of some $11 trillion, the STOXX covers a universe of 600 developed-market European companies, and includes UK, Swiss and Scandinavian shares.

  • Reuters

    India pharma companies develop versions of Wegovy to get in on weight-loss windfall

    Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.